Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2452

Sort by

Sort Order Select

Journal Articles

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Lingzhi Yan, Zhi Yan, Jingjing Shang, Xiaolan Shi, Song Jin, Liqing Kang, Su Qu, Jin Zhou, Huizhu Kang, Ruju Wang, Ying Yao, Jing Wang, Weiqin Yao, Guanghua Chen, Lei Yu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD

Blood (2019) 134 (Supplement_1): 578.

https://doi.org/10.1182/blood-2019-129740

Published: 2019

Journal Articles

Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT

Arnon Nagler, MD MSc, Myriam Labopin, MD, Emanuele Angelucci, MD, Yener Koc, MD, Mutlu Arat, MD, Pietro Pioltelli, MD, Simona Sica, MD, Zafer Gülbas, MD, Johanna Tischer, MD, Paolo Bernasconi, MD, Jiri Pavlu, MDMRCP,FRCPath, Gerard Socie, MD PhD, Didier Blaise, MD PhD, Luigi Rigacci, MD, Massimo Martino, MD, José Luis Díez-Martín, MD PhD, Zinaida Peric, MD PhD, Sebastian Giebel, MD PhD, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 589.

https://doi.org/10.1182/blood-2019-121644

Published: 2019

Journal Articles

Time-Restricted Versus Standard Duration Immunosuppression after Allogeneic Hematopoietic Stem Cell Transplantation: Results from the Prospective Randomized Phase III HOVON-96 Trial

Cornelis N. De Jong, MD, Ellen Meijer, MD PhD, Katerina Bakunina, Erfan Nur, MD PhD, Marinus van Marwijk Kooij, MD PhD, Marco De Groot, MD PhD, Michel Van Gelder, MD PhD, Johan A. Maertens, MD PhD, Jurgen H.E. Kuball, MD PhD, Dries Deeren, MD PhD, Bronno Van Der Holt, PhD, Jan J Cornelissen, MD PhD, Annoek E.C. Broers, MD PhD

Blood (2019) 134 (Supplement_1): 371.

https://doi.org/10.1182/blood-2019-130872

Published: 2019

Journal Articles

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Blood (2019) 134 (Supplement_1): 258.

https://doi.org/10.1182/blood-2019-126172

Published: 2019

Journal Articles

Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leukemia Undergoing Myeloablative Allogeneic Transplantation

Cindy Lynn Hickey, MDFRCPC, Haesook T. Kim, PhD, Vincent T. Ho, MD, Sarah Nikiforow, MD PhD, Mahasweta Gooptu, MD, John Koreth, MBBS, DPhil, Jerome Ritz, MD, Rizwan Romee, MD PhD, Edwin P. Alyea, III, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD, Corey Cutler, MD MPH, FRCPC

Blood (2019) 134 (Supplement_1): 263.

https://doi.org/10.1182/blood-2019-122257

Published: 2019

Journal Articles

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from HLA-Identical Sibling Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT

Blood (2019) 134 (Supplement_1): 148.

https://doi.org/10.1182/blood-2019-123269

Published: 2019

Journal Articles

Targeting Bcl-2 and CD38 As Part of Personalized HSCT Conditioning Regimen in Chemorefractory Acute Leukemia in Children

Larisa Shelikhova, MD, Rimma Khismatullina, MD, Michael Maschan, MD MSc, Alexey A. Maschan, MD, Irina Kalinina, MD, Elena Kurnikova, Yakov Muzalevsky, Alexey Kazachenok, Dmitriy Pershin, Alexander Popov, MD PhD, Galina Novichkova, MD PhD, Dmitriy Balashov, MD PhD, Daria Shasheleva, MD, Svetlana Kashpor, Evgeny Gluhanyuk

Blood (2019) 134 (Supplement_1): 150.

https://doi.org/10.1182/blood-2019-129765

Published: 2019

Journal Articles

Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial

Brian Kornblit, MD PhD, Barry Storer, Michael B. Maris, MD, Niels Smedegaard Andersen, MD PhD, Thomas R. Chauncey, MD PhD, Effie W. Petersdorf, MD, Ann Woolfrey, MD, David G. Maloney, MD PhD, Rainer Storb, MD, Brenda M Sandmaier, MD

Blood (2019) 134 (Supplement_1): 369.

https://doi.org/10.1182/blood-2019-123196

Published: 2019

Journal Articles

Results of Unrelated Donor Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Europe on Behalf of Paediatric Diseases (PDWP) and Inborn Errors Working Parties (IEWP) of the EBMT

Blood (2019) 134 (Supplement_1): 4583.

https://doi.org/10.1182/blood-2019-121952

Published: 2019

Journal Articles

Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant Outcome

Wei Wang, Paul Auer, PhD, Stephen R. Spellman, MS, Karen-Sue B. Carlson, MD PhD, Aziz Nazha, MD, Martin Maiers, MS, Yung-Tsi Bolon, Wael Saber, MD MS

Blood (2019) 134 (Supplement_1): 4557.

https://doi.org/10.1182/blood-2019-127124

Published: 2019

Journal Articles

Absolute Lymphocyte Count (ALC) Less Than 100 Predicts Adverse Transplant Outcomes with Rabbit Thymoglobulin in Patients Undergoing Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Dipenkumar Modi, MD, Malini Surapaneni, MD, Seongho Kim, PhD, Lois Ayash, MD, Asif Alavi, MD, Andrew Kin, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2019) 134 (Supplement_1): 4527.

https://doi.org/10.1182/blood-2019-125437

Published: 2019

Journal Articles

CD34+ Cell Dose Effects on Clinical Outcomes of Patients with Acute Myeloid Leukemia after T-Replete Haploidentical Allogeneic Hematopoietic Stemcell Transplantation Using Peripheral Blood Stem Cells. a Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Enrico Maffini, MD, Myriam Labopin, MD, Didier Blaise, MD PhD, Fabio Ciceri, MD, Zafer Gulbas, MD, Etienne Daguindau, Stephanie Nguyen-Quoc, MD, Patrice Chevallier, MD, Gerard Socie, MD PhD, Mercedes Colorado, MD, Yener Koc, MD, Francesco Lanza, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 4586.

https://doi.org/10.1182/blood-2019-123987

Published: 2019

Journal Articles

Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allotransplant Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection

Patrice Chevallier, MD, Pierre Peterlin, Alice Garnier, MD, Amandine Le Bourgeois, MD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, MD, Cyrille Touzeau, MD, Thomas Gastinne, MD, Anne Lok, MD, Benoit Tessoulin, MD PhD, Yannick Le Bris, PharmD, Marie C Bene, PharmSci, PhD, Steven Le Gouill, MD PhD, Philippe Moreau, MD, Thierry Guillaume, MD PhD

Blood (2019) 134 (Supplement_1): 4528.

https://doi.org/10.1182/blood-2019-125787

Published: 2019

Journal Articles

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Maria Queralt Salas, MD, Shiyi Chen, Wilson Lam, MD, David Loach, MD, Fotios V. Michelis, MD PhD, Zeyad Al-Shaibani, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM, Rajat Kumar, MD, Jonas Mattsson, MD, Arjun Law, MDDM

Blood (2019) 134 (Supplement_1): 4590.

https://doi.org/10.1182/blood-2019-126236

Published: 2019

Journal Articles

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

Luke Eastburg, MD, David A. Russler-Germain, MDPhDBS, Ramzi Abboud, MD, Peter Westervelt, MD PhD, John F. DiPersio, MD PhD, Michael W. Becker, MD, Neha Kumar, MD, Omar S. Aljitawi, MD, Jeffrey R. Andolina, MD MS, Thomas J Fountaine, MD, Jane L. Liesveld, MD, Eric Huselton, MD

Blood (2019) 134 (Supplement_1): 4496.

https://doi.org/10.1182/blood-2019-129872

Published: 2019

Journal Articles

In-Vivo Adsorption of Iso-Haemagglutinin (IHA) Antibodies By Donor Type Red Cell Transfusion during Conditioning Is a Safe and Effective Method to Overcome Major ABO Incompatibility-Related Acute Hemolytic Reactions in Stem Cell Transplant Using Bone Marrow As Stem Cell Graft Source

Pallavi Mehta, MD DM, Stalin Ramprakash, MD MBBS, C Raghuram, Deepa Trivedi, MD, Priya Marwah, Rajpreet Soni, Rakesh Dhanya, BE, Rajat Kumar Agarwal, BS, Lawrence Faulkner, MD

Blood (2019) 134 (Supplement_1): 4467.

https://doi.org/10.1182/blood-2019-131118

Published: 2019

Journal Articles

Absence of Damaging Effects of Stem Cell Donation in Unrelated Donors Assessed By FISH and Gene Variance Screening

Elisabeth P. Nacheva, MD PhD, Trudy Ahyee, C Navarette, Juanah Addada, MDPhDFRCP, Rachel Pawson, Richard Syzdlo, PhD, Stephen Mackinnon, MD, Bronwen E. Shaw, MD PhD, J. Alejandro Madrigal, MDPhDDSc,FRCP,FRCPath

Blood (2019) 134 (Supplement_1): 4474.

https://doi.org/10.1182/blood-2019-131931

Published: 2019

Journal Articles

Impact of Graft Versus Host Disease on Outcome of Allogeneic Haematopoietic Stem Cell Transplantation for Thalassemia Major - Comparison of Bone Marrow Vs Peripheral Blood Stem Cell Grafts

Fouzia N., Uday Prakash Kulkarni, MD DM, Anup Joseph Devasia, MD DM, Anu Korula, MD DM, Kavitha M Lakshmi, MSc, Aby Abraham, MD DM, Biju George, MDDM, Vikram Mathews, MD DM, Alok Srivastava, MD,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 4537.

https://doi.org/10.1182/blood-2019-130491

Published: 2019

Journal Articles

Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era

Sanghee Hong, MD, Lisa Rybicki, MS, Donna Corrigan, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Robert M. Dean, MD, Brian T. Hill, MD, Brad Pohlman, MD, Deepa Jagadeesh, MDMPH, Faiz Anwer, MD, Navneet S. Majhail, MD MS

Blood (2019) 134 (Supplement_1): 4567.

https://doi.org/10.1182/blood-2019-124533

Published: 2019

Journal Articles

Improved Gvhd Free, Relapse Free Survival Using Dual T-Cell Depletion with ATG and Ptcy in Matched Unrelated Donor RIC Allo-HSCT

Maria Queralt Salas, MD, Wilson Lam, MD, Arjun Law, MDDM, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Zeyad Al-Shaibani, David Loach, MD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Auro Viswabandya, MDDM

Blood (2019) 134 (Supplement_1): 4594.

https://doi.org/10.1182/blood-2019-128720

Published: 2019

NARROW

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT

Time-Restricted Versus Standard Duration Immunosuppression after Allogeneic Hematopoietic Stem Cell Transplantation: Results from the Prospective Randomized Phase III HOVON-96 Trial

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leukemia Undergoing Myeloablative Allogeneic Transplantation

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from HLA-Identical Sibling Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT

Targeting Bcl-2 and CD38 As Part of Personalized HSCT Conditioning Regimen in Chemorefractory Acute Leukemia in Children

Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial

Results of Unrelated Donor Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Europe on Behalf of Paediatric Diseases (PDWP) and Inborn Errors Working Parties (IEWP) of the EBMT

Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant Outcome

Absolute Lymphocyte Count (ALC) Less Than 100 Predicts Adverse Transplant Outcomes with Rabbit Thymoglobulin in Patients Undergoing Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allotransplant Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

In-Vivo Adsorption of Iso-Haemagglutinin (IHA) Antibodies By Donor Type Red Cell Transfusion during Conditioning Is a Safe and Effective Method to Overcome Major ABO Incompatibility-Related Acute Hemolytic Reactions in Stem Cell Transplant Using Bone Marrow As Stem Cell Graft Source

Absence of Damaging Effects of Stem Cell Donation in Unrelated Donors Assessed By FISH and Gene Variance Screening

Impact of Graft Versus Host Disease on Outcome of Allogeneic Haematopoietic Stem Cell Transplantation for Thalassemia Major - Comparison of Bone Marrow Vs Peripheral Blood Stem Cell Grafts

Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era

Improved Gvhd Free, Relapse Free Survival Using Dual T-Cell Depletion with ATG and Ptcy in Matched Unrelated Donor RIC Allo-HSCT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only